Levodopa in Parkinson's Disease: Current Status and Future Developments

Nicola Tambasco, Michele Romoli, Paolo Calabresi, Nicola Tambasco, Michele Romoli, Paolo Calabresi

Abstract

Background: Ever since the pioneering reports in the 60s, L-3,4-Dioxyphenylalanine (levodopa) has represented the gold standard for the treatment of Parkinson's Disease (PD). However, long-term levodopa (LD) treatment is frequently associated with fluctuations in motor response with serious impact on patient quality of life. The pharmacokinetic and pharmacodynamic properties of LD are pivotal to such motor fluctuations: discontinuous drug delivery, short half-life, poor bioavailability, and narrow therapeutic window are all crucial for such fluctuations. During the last 60 years, several attempts have been made to improve LD treatment and avoid long-term complications.

Methods: Research and trials to improve the LD pharmacokinetic since 1960s are reviewed, summarizing the progressive improvements of LD treatment.

Results: Inhibitors of peripheral amino acid decarboxylase (AADC) have been introduced to achieve proper LD concentration in the central nervous system reducing systemic adverse events. Inhibitors of catechol-O-methyltransferase (COMT) increased LD half-life and bioavailability. Efforts are still being made to achieve a continuous dopaminergic stimulation, with the combination of oral LD with an AADC inhibitor and a COMT inhibitor, or the intra-duodenal water-based LD/ carbidopa gel. Further approaches to enhance LD efficacy are focused on new non-oral administration routes, including nasal, intra-duodenal, intrapulmonary (CVT-301) and subcutaneous (ND0612), as well as on novel ER formulations, including IPX066, which recently concluded phase III trial.

Conclusion: New LD formulations, oral compounds as well as routes have been tested in the last years, with two main targets: achieve continuous dopaminergic stimulation and find an instant deliver route for LD.

Keywords: DM-1992; IPX066; LCIG; ODM-101; Parkinson`s disease; XP21279; levodopa; pharmacology..

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

References

    1. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21) Suppl. 4:S1–S136. [ WNL.0b013e3181a1d44c]. [PMID: 19470958].
    1. Rajput A.H., Birdi S. Epidemiology of Parkinson’s disease. Parkinsonism Relat. Disord. 1997;3(4):175–186. [ 10.1016/S1353-8020(97)00029-1]. [PMID: 18591073].
    1. Jellinger K.A. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural Transm. Suppl. 2007;72(72):91–104. [PMID: 17982882].
    1. Nagatsu T., Levitt M., Udenfriend S. Tyrosine hydroxylase: The initial step in norepinephrine biosynthesis. J. Biol. Chem. 1964;239:2910–2917. [PMID: 14216443].
    1. Cooksey C.J., Garratt P.J., Land E.J., Pavel S., Ramsden C.A., Riley P.A., Smit N.P. Evidence of the indirect formation of the catecholic intermediate substrate responsible for the auto-activation kinetics of tyrosinase. J. Biol. Chem. 1997;272(42):26226–26235. []. [PMID: 9334191].
    1. Nagatsua T., Sawadab M. L-dopa therapy for Parkinson’s disease: past, present, and future. Parkinsonism Relat. Disord. 2009;15(Suppl. 1):S3–S8. []. [PMID: 19131039].
    1. Lovenberg W., Weissbach H., Udenfriend S. Aromatic L-amino acid decarboxylase. J. Biol. Chem. 1962;237:89–93. [PMID: 14466899].
    1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1871.
    1. Sano I., Gamo T., Kakimoto Y., Taniguchi K., Takesada M., Nishinuma K. Distribution of catechol compounds in human brain. Biochim. Biophys. Acta. 1959;32:586–587. [ 10.1016/0006-3002(59)90652-3]. [PMID: 14441532].
    1. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids. 2002;23(1-3):65–70. []. [PMID: 12373520].
    1. Abbott A. Levodopa: the story so far. Nature. 2010;466(7310):S6–S7. []. [PMID: 20739934].
    1. Guggenheim M. Dioxyphenylalanin, eine neue Amino- säure aus Vicia faba. Hoppe Seylers Z. Physiol. Chem. 1913;88:276–284. [].
    1. Oster K.A., Sorkin S.Z. The effects of intravenous injection of L-dopa upon blood pressure. Proc. Soc. Exp. Biol. Med. 1942;51:67–71. [].
    1. Holtz P., Credner K., Kroneberg G. Über das sympathiko-mimetische pressorische Prinzip des Hirn (“Urosympathin”). Arch. Exp. Path. Pharmik. 1947;204:228–243. [. 1007/BF00738347].
    1. LeWitt P.A., Fahn S. Levodopa therapy for Parkinson disease: A look backward and forward. Neurology. 2016;86(14) Suppl. 1:S3–S12. []. [PMID: 27044648].
    1. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydro-xyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957;180(4596):1200. [ 1801200a0]. [PMID: 13483658].
    1. Carlsson A. Monoamine-depleting drugs. Pharmacol. Ther. [B] 1975;1(3):393–400. [ 90045-8]. [PMID: 772709].
    1. Carlsson A., Hillarp N.A. Release of adenosine triphosphate along with adrenaline and noradrenaline following stimulation of the adrenal medulla. Acta Physiol. Scand. 1956;37(2-3):235–239. [http:// ]. [PMID: 13361903].
    1. Carlsson A. Treatment of Parkinson’s with L-DOPA. The early discovery phase, and a comment on current problems. J. Neural Transm. (Vienna) 2002;109(5-6):777–787. [ 10.1007/s007020200064]. [PMID: 12111467].
    1. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 1959;11(2, Part 2):490–493. [PMID: 13667431].
    1. Sano I., Gamo T., Kakimoto Y., Taniguchi K., Takesada M., Nishinuma K. Distribution of catechol compounds in human brain. Biochim. Biophys. Acta. 1959;32:586–587. [. 1016/0006-3002(59)90652-3]. [PMID: 14441532].
    1. Sano I. Biochemistry of the extrapyramidal system. Shinkei Kenkyu No Shinnpo (Adv Neurol Sci), 1960, 5, 42-48. (Translated into English by Sano, A. Parkinsonism Relat. Disord. 2000;6:303–306.
    1. Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und Dopamin (3-Hydroxytyramin) im nehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidaren systems. Klin. Wochenschr. 1960;38:1236–1239. [ BF01485901]. [PMID: 13726012].
    1. Birkmayer W., Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat. Disord. 1998;4(2):59–60. [http://dx.doi. org/10.1016/S1353-8020(98)00013-3]. [PMID: 18591089].
    1. McGeer P.L., Zeldowicz L.R. Administration of dihydroxyphenylalanine to parkinsonian patients. Can. Med. Assoc. J. 1964;90:463–466. [PMID: 14120951].
    1. Bertler A., Rosengren E. Possible role of brain dopamine. Pharmacol. Rev. 1966;18(1):769–773. [PMID: 5904188].
    1. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 1967;276(7):374–379. []. [PMID: 5334614].
    1. Hauser R.A. Levodopa: past, present, and future. Eur. Neurol. 2009;62(1):1–8. []. [PMID: 19407449].
    1. Tambasco N., Belcastro V., Gallina A., Castrioto A., Calabresi P., Rossi A. Levodopa-induced breathing, cognitive and behavioral changes in Parkinson’s disease. J. Neurol. 2011;258(12):2296–2299. []. [PMID: 21647729].
    1. LeWitt P.A. Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov. Disord. 2015;30(1):64–72. []. [PMID: 25449210].
    1. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N. Engl. J. Med. 1969;280(7):337–345. []. [PMID: 4178641].
    1. Yahr M.D., Duvoisin R.C., Schear M.J., Barrett R.E., Hoehn M.M. Treatment of parkinsonism with levodopa. Arch. Neurol. 1969;21(4):343–354. [. 00480160015001]. [PMID: 5820999].
    1. Lloyd K.G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J. Pharmacol. Exp. Ther. 1975;195(3):453–464. [PMID: 489].
    1. Hornykiewicz O. How does L-dopa work? Philadelphia: Barbeau A, McDowell FH; 1970. pp. 393–399.
    1. Fahn S. Levodopa in the treatment of Parkinson’s disease. J. Neural Transm. Suppl. 2006;71(71):1–15. [PMID: 17447410].
    1. Shoulson I., Glaubiger G.A., Chase T.N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975;25(12):1144–1148. []. [PMID: 812004].
    1. Kurlan R., Rubin A.J., Miller C., Rivera-Calimlim L., Clarke A., Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann. Neurol. 1986;20(2):262–265. []. [PMID: 3752968].
    1. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 1984;7(1):35–49. [ 00002826-198403000-00002]. [PMID: 6367973].
    1. Leenders K.L., Poewe W.H., Palmer A.J., Brenton D.P., Frackowiak R.S. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann. Neurol. 1986;20(2):258–262. [. 1002/ana.410200212]. [PMID: 3092728].
    1. Camargo S.M.R., Vuille-dit-Bille R.N., Mariotta L., Ramadan T., Huggel K., Singer D., Götze O., Verrey F. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson’s disease. J. Pharmacol. Exp. Ther. 2014;351(1):114–123. [. 216317]. [PMID: 25073474].
    1. Calne D.B., Karoum F., Ruthven C.R.J., Sandler M. The metabolism of orally administered L-Dopa in Parkinsonism. Br. J. Pharmacol. 1969;37(1):57–68. []. [PMID: 5343357].
    1. Bartholini G., Burkard W.P., Pletscher A., Bates H.M. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature. 1967;215(5103):852–853. []. [PMID: 6049735].
    1. Nutt J.G., Woodward W.R., Anderson J.L. Effect of carbidopa on pharmacokinetics of intravenously administered levodopa: implications for mechanism of action of carbidopa in the treatment of Parkinsonism. Ann. Neurol. 1985;13:537–544. [http://dx.doi. org/10.1002/ana.410180505]. [PMID: 4073849].
    1. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(4) Suppl. 1:S19–S32. [. suppl_1.S19]. [PMID: 11909982].
    1. Pletscher A., DaPrada M. Pharmacotherapy of Parkinson’s disease: research from 1960 to 1991. Acta Neurol. Scand. Suppl. 1993;146:26–31. [PMID: 8101413].
    1. Papavasiliou P.S., Cotzias G.C., Düby S.E., Steck A.J., Fehling C., Bell M.A. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med. 1972;286(1):8–14. []. [PMID: 4550085].
    1. Birkmayer W., Mentasti M. 1970.
    1. Huebert N.D., Palfreyman M.G., Haegele K.D. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine. Drug Metab. Dispos. 1983;11(3):195–200. [PMID: 6135575].
    1. Salat D., Tolosa E. Levodopa in the treatment of Parkinson’s disease: current status and new developments. J. Parkinsons Dis. 2013;3(3):255–269. [PMID: 23948989].
    1. Markham C., Diamond S.G., Treciokas L.J. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch. Neurol. 1974;31(2):128–133. [. 00490380076010]. [PMID: 4834974].
    1. Lieberman A., Goodgold A., Jonas S., Leibowitz M. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson’s disease. Neurology. 1975;25(10):911–916. []. [PMID: 1101099].
    1. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9(11):1106–1117. []. [PMID: 20880751].
    1. Cedarbaum J.M., Kutt H., Dhar A.K., Watkins S., McDowell F.H. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin. Neuropharmacol. 1986;9(2):153–159. [ 10.1097/00002826-198604000-00006]. [PMID: 3085927].
    1. Ward C.D., Trombley I.K., Calne D.B., Kopin I.J. L-dopa decarboxylation in chronically treated patients. Neurology. 1984;34(2):198–201. []. [PMID: 6538008].
    1. Dingemanse J., Kleinbloesem C.H., Zürcher G., Wood N.D., Crevoisier C. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br. J. Clin. Pharmacol. 1997;44(1):41–48. [. 1046/j.1365-2125.1997.00610.x]. [PMID: 9241095].
    1. Eberling J.L., Jagust W.J., Christine C.W., Starr P., Larson P., Bankiewicz K.S., Aminoff M.J. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980–1983. [. 29287.ff]. [PMID: 18401019].
    1. Mittermeyer G., Christine C.W., Rosenbluth K.H., Baker S.L., Starr P., Larson P., Kaplan P.L., Forsayeth J., Aminoff M.J., Bankiewicz K.S. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson’s disease. Hum. Gene Ther. 2012;23(4):377–381. []. [PMID: 22424171].
    1. Palfi S., Gurruchaga J.M., Ralph G.S., Lepetit H., Lavisse S., Buttery P.C., Watts C., Miskin J., Kelleher M., Deeley S., Iwamuro H., Lefaucheur J.P., Thiriez C., Fenelon G., Lucas C., Brugières P., Gabriel I., Abhay K., Drouot X., Tani N., Kas A., Ghaleh B., Le Corvoisier P., Dolphin P., Breen D.P., Mason S., Guzman N.V., Mazarakis N.D., Radcliffe P.A., Harrop R., Kingsman S.M., Rascol O., Naylor S., Barker R.A., Hantraye P., Remy P., Cesaro P., Mitrophanous K.A. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014;383(9923):1138–1146. [ S0140-6736(13)61939-X]. [PMID: 24412048].
    1. Contin M., Martinelli P. Pharmacokinetics of levodopa. J. Neurol. 2010;257(Suppl. 2):S253–S261. [ s00415-010-5728-8]. [PMID: 21080186].
    1. Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–174. [ s40265-014-0343-0]. [PMID: 25559423].
    1. Männistö P.T., Kaakkola S. New selective COMT inhibitors: useful adjuncts for Parkinson’s disease? Trends Pharmacol. Sci. 1989;10(2):54–56. []. [PMID: 2655238].
    1. Lee E.S., Chen H., King J., Charlton C. The role of 3-O-methyldopa in the side effects of L-dopa. Neurochem. Res. 2008;33(3):401–411. []. [PMID: 17713853].
    1. Tambasco N., Muti M., Chiarini P., Tarducci R., Caproni S., Castrioto A., Nigro P., Parnetti L., Floridi P., Rossi A., Calabresi P. Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study. 2014.
    1. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., Hallett M., Miyasaki J., Stevens J., Weiner W.J. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983–995. [ 10.1212/01.wnl.0000215250.82576.87]. [PMID: 16606909].
    1. Kuruma I., Bartholini G., Tissot R., Pletscher A. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin. Pharmacol. Ther. 1971;12(4):678–682. [. 1002/cpt1971124678]. [PMID: 5567811].
    1. Bonifácio M.J., Palma P.N., Almeida L., Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev. 2007;13(3):352–379. [. 1111/j.1527-3458.2007.00020.x]. [PMID: 17894650].
    1. Freitas M.E., Ruiz-Lopez M., Fox S.H. Novel levodopa formulations for Parkinson’s Disease. CNS Drugs. 2016;30(11):1079–1095. []. [PMID: 27743318].
    1. LeWitt P.A., Jennings D., Lyons K.E., Pahwa R., Rabinowicz A.L., Wang J., Guarnieri M., Hubble J.P., Murck H. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov. Disord. 2009;24(9):1319–1324. [http:// ]. [PMID: 19412946].
    1. Obeso J.A., Rodriguez-Oroz M.C., Chana P., Lera G., Rodriguez M., Olanow C.W. The evolution and origin of motor complications in Parkinson’s disease. Neurology. 2000;55(11) Suppl. 4:S13–S20. [PMID: 11147505].
    1. Olanow C.W., Obeso J.A., Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat. Clin. Pract. Neurol. 2006;2(7):382–392. [ 10.1038/ncpneuro0222]. [PMID: 16932589].
    1. Pilleri M., Antonini A. Novel levodopa formulations in the treatment of Parkinson’s disease. Expert Rev. Neurother. 2014;14(2):143–149. []. [PMID: 24428803].
    1. Contin M., Riva R., Albani F., Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson’s disease. Clin. Pharmacokinet. 1996;30(6):463–481. []. [PMID: 8792058].
    1. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677–687. [http:// ]. [PMID: 16857573].
    1. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin. Pharmacokinet. 2006;45(2):109–136. []. [PMID: 16485914].
    1. Meloni M., Solla P., Mascia M.M., Marrosu F., Cannas A. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson’s disease. Parkinsonism Relat. Disord. 2016;37:92–96. [PMID: 28063683].
    1. Olanow W., Schapira A.H., Rascol O. Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci. 2000;23(10) Suppl.:S117–S126. []. [PMID: 11052229].
    1. Jenner P., McCreary A.C., Scheller D.K. Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression. J. Neural Transm. (Vienna) 2011;118(12):1691–1702. [ s00702-011-0703-9]. [PMID: 21881838].
    1. Rascol O., Korczyn A., De Deyn P.P., Lang A. Incidence of dyskinesias in a 10-year naturalistic follow-up of patients with early Parkinson’s disease (PD) initially receiving ropinirole compared with L-dopa. Mov. Disord. 2005;20(Suppl. 10):S63.
    1. Goetz C.G., Koller W.C., Poewe W. Management of Parkinson’s disease: an evidence-based review. Mov. Disord. 2002;17(Suppl. 4):S1–S166. [PMID: 12211134].
    1. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med. 2004;351(24):2498–2508. []. [PMID: 15590952].
    1. Goetz C.G., Poewe W., Rascol O., Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov. Disord. 2005;20(5):523–539. []. [PMID: 15818599].
    1. Sage J.I., Mark M.H. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson’s disease: a double-blind, crossover study. Clin. Neuropharmacol. 1988;11(2):174–179. []. [PMID: 3378226].
    1. Ahlskog J.E., Muenter M.D., McManis P.G., Bell G.N., Bailey P.A. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson’s disease. Mayo Clin. Proc. 1988;63(9):876–886. []. [PMID: 3045435].
    1. Hutton J.T., Morris J.L., Bush D.F., Smith M.E., Liss C.L., Reines S. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson’s disease. Neurology. 1989;39(11) Suppl. 2:67–72. [PMID: 2685652].
    1. Feldman R.G., Mosbach P.A., Kelly M.R., Thomas C.A., Saint Hilaire M.H. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson’s disease. Neurology. 1989;39(11) Suppl. 2:96–101. [PMID: 2685655].
    1. Lieberman A., Gopinathan G. Miller, E.; Neophytides, A.; Baumann, G.; Chin, L. Ran- domized double-blind cross-over study of Sinemet-Controlled Release (CR4 50/ 200) versus Sinemet 25/100 in Parkinson’s disease. Eur. Neurol. 1990;30:75–78. [http://dx. ]. [PMID: 2340838].
    1. Jankovic J., Schwartz K., Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov. Disord. 1989;4(4):303–309. []. [PMID: 2682215].
    1. Wolters E.C., Horstink M.W., Roos R.A., Jansen E.N. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson’s disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. Clin. Neurol. Neurosurg. 1992;94(3):205–211. []. [PMID: 1327609].
    1. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson’s disease. Clin. Neuropharmacol. 1989;12(6):498–505. [PMID: 2691069].
    1. Dupont E., Andersen A., Boas J., Boisen E., Borgmann R., Helgetveit A.C., Kjaer M.O., Kristensen T.N., Mikkelsen B., Pakkenberg H., Presthus J., Stien R., Worm-Petersen J., Buch D. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol. Scand. 1996;93(1):14–20. [ 10.1111/j.1600-0404.1996.tb00163.x]. [PMID: 8825266].
    1. Block G., Liss C., Reines S., Irr J., Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. Eur. Neurol. 1997;37(1):23–27. []. [PMID: 9018028].
    1. Koller W.C., Hutton J.T., Tolosa E., Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology. 1999;53(5):1012–1019. []. [PMID: 10496260].
    1. Djaldetti R., Inzelberg R., Giladi N., Korczyn A.D., Peretz-Aharon Y., Rabey M.J., Herishano Y., Honigman S., Badarny S., Melamed E. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson’s disease. Mov. Disord. 2002;17(2):297–302. [. 1002/mds.10075]. [PMID: 11921115].
    1. Stocchi F., Fabbri L., Vecsei L., Krygowska-Wajs A., Monici Preti P.A., Ruggieri S.A. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin. Neuropharmacol. 2007;30(1):18–24. []. [PMID: 17272966].
    1. Stocchi F., Vacca L., Grassini P., Pawsey S., Whale H., Marconi S., Torti M. L-Dopa pharmacokinetic profile with effervescent melevodopa/carbidopa versus standard-release levodopa/ carbidopa tablets in Parkinson’s Disease: A Randomised Study. Parkinsons Dis. 2015;2015:369465. [ 2015/369465]. [PMID: 26171276].
    1. Silva F. Effects of CHF 1512, a new combination of levodopa methylester and carbidopa, on motor fluctuations in Parkinson’s disease: results from a European study. Mov. Disord. 2006;21(13):119–120.
    1. Kianirad Y., Simuni T. Novel approaches to optimization of levodopa therapy for Parkinson’s Disease. Curr. Neurol. Neurosci. Rep. 2016;16(4):34. []. [PMID: 26898686].
    1. Hauser R.A., Hsu A., Kell S., Espay A.J., Sethi K., Stacy M., Ondo W., O’Connell M., Gupta S. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–356. [ 70025-5]. [PMID: 23485610].
    1. Pahwa R., Lyons K.E., Hauser R.A., Fahn S., Jankovic J., Pourcher E., Hsu A., O’Connell M., Kell S., Gupta S. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat. Disord. 2014;20(2):142–148. []. [PMID: 24055014].
    1. Hauser R.A., Ellenbogen A.L., Metman L.V., Hsu A., O’Connell M.J., Modi N.B., Yao H.M., Kell S.H., Gupta S.K. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov. Disord. 2011;26(12):2246–2252. []. [PMID: 21755537].
    1. Mao Z., Hsu A., Gupta S., Modi N.B. Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson’s disease. J. Clin. Pharmacol. 2013;53(5):523–531. []. [PMID: 23426902].
    1. Stocchi F., Hsu A., Khanna S., Ellenbogen A., Mahler A., Liang G., Dillmann U., Rubens R., Kell S., Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat. Disord. 2014;20(12):1335–1340. []. [PMID: 25306200].
    1. Nausieda P.A., Hsu A., Elmer L., Gil R.A., Spiegel J., Singer C., Khanna S., Rubens R., Kell S., Modi N.B., Gupta S. Conversion to IPX066 from standard levodopa formulations in advanced Parkinson’s disease: experience in clinical trials. J. Parkinsons Dis. 2015;5(4):837–845. []. [PMID: 26444090].
    1. Waters C.H., Nausieda P., Dzyak L., Spiegel J., Rudzinska M., Silver D.E., Tsurkalenko E.S., Kell S., Hsu A., Khanna S., Gupta S. Long-term treatment with extended-release carbidopa- levodopa (IPX066) in early and advanced Parkinson’s disease: a 9-month open-label extension trial. CNS Drugs. 2015;29(4):341–350. []. [PMID: 25895021].
    1. Greig S.L., McKeage K. Carbidopa/levodopa ER capsules (Rytary®, NumientTM): a review in Parkinson’s disease. CNS Drugs. 2016;30(1):79–90. []. [PMID: 26692288].
    1. LeWitt P.A., Giladi N., Gurevich T. Accordion pill carbidopa/ levodopa (AP CD/LD) for treatment of advanced Parkinson’s disease (PD). Mov. Disord. 2014;29(1):S248. [PMID: 24339234].
    1. LeWitt P.A., Friedman H., Giladi N. Accordion pill carbidopa/ levodopa for improved treatment of advanced Parkinson’s disease symptoms. Mov. Disord. 2012;27(1):S408.
    1. Chen C., Cowles V.E., Sweeney M., Stolyarov I.D., Illarioshkin S.N. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin. Neuropharmacol. 2012;35(2):67–72. [ 10.1097/WNF.0b013e31824523de]. [PMID: 22377973].
    1. Verhagen Metman L., Stover N., Chen C., Cowles V.E., Sweeney M. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson’s disease. Mov. Disord. 2015;30(9):1222–1228. []. [PMID: 25847690].
    1. Lewitt P.A., Ellenbogen A., Chen D., Lal R., McGuire K., Zomorodi K., Luo W., Huff F.J. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin. Neuropharmacol. 2012;35(3):103–110. []. [PMID: 22406623].
    1. LeWitt P.A., Huff F.J., Hauser R.A., Chen D., Lissin D., Zomorodi K., Cundy K.C. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov. Disord. 2014;29(1):75–82. []. [PMID: 24339234].
    1. Muller T., Kuoppamaki M., Vahteristio M., Aho V. Novel levodopa product ODM-101 vs levodopa/carbidopa/entacapone in Parkinson’s disease with response fluctuations. Mov. Disord. 2013;28:S146.
    1. Bredenberg S., Nyholm D., Aquilonius S.M., Nyström C. An automatic dose dispenser for microtablets--a new concept for individual dosage of drugs in tablet form. Int. J. Pharm. 2003;261(1-2):137–146. []. [PMID: 12878402].
    1. van Riet-Nales D.A., Hussain N., Sundberg K.A., Eggenschwyler D., Ferris C., Robert J.L., Cerreta F. Regulatory incentives to ensure better medicines for older people: From ICH E7 to the EMA reflection paper on quality aspects. Int. J. Pharm. 2016;512(2):343–351. [. 05.001]. [PMID: 27150947].
    1. Aquilonius S.M., Nyholm D. Development of new levodopa treatment strategies in Parkinson’s disease-from bedside to bench to bedside. Ups. J. Med. Sci. 2017;122(2):71–77. [http://dx. ]. [PMID: 28276779].
    1. Nyholm D., Ehrnebo M., Lewander T., Trolin C.G., Bäckström T., Panagiotidis G., Spira J., Nyström C., Aquilonius S.M. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurol. Scand. 2013;127(2):124–132. []. [PMID: 22762460].
    1. Seeberger L.C., Hauser R.A. Carbidopa levodopa enteral suspension. Expert Opin. Pharmacother. 2015;16(18):2807–2817. [http:// ]. [PMID: 26595228].
    1. Nyholm D., Lennernäs H. Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin. Drug Metab. Toxicol. 2008;4(2):193–203. []. [PMID: 18248312].
    1. Nilsson D., Hansson L.E., Johansson K., Nyström C., Paalzow L., Aquilonius S.M. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol. Scand. 1998;97(3):175–183. [http://dx.doi. org/10.1111/j.1600-0404.1998.tb00633.x]. [PMID: 9531434].
    1. Nyholm D., Odin P., Johansson A., Chatamra K., Locke C., Dutta S., Othman A.A. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J. 2013;15(2):316–323. [. 1208/s12248-012-9439-1]. [PMID: 23229334].
    1. Wirdefeldt K., Odin P., Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs. 2016;30:1–24. [PMID: 26715389].
    1. Olanow C.W., Kieburtz K., Odin P., Espay A.J., Standaert D.G., Fernandez H.H., Vanagunas A., Othman A.A., Widnell K.L., Robieson W.Z., Pritchett Y., Chatamra K., Benesh J., Lenz R.A., Antonini A. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149. [http://dx. ]. [PMID: 24361112].
    1. Fernandez H.H., Vanagunas A., Odin P., Espay A.J., Hauser R.A., Standaert D.G., Chatamra K., Benesh J., Pritchett Y., Hass S.L., Lenz R.A. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism Relat. Disord. 2013;19(3):339–345. [ 10.1016/j.parkreldis.2012.11.020]. [PMID: 23287001].
    1. Antonini A., Yegin A., Preda C., Bergmann L., Poewe W. GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-car- bidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat. Disord. 2015;21:231–235. [. 2014.12.012]. [PMID: 25585993].
    1. Zibetti M., Merola A., Ricchi V., Marchisio A., Artusi C.A., Rizzi L., Montanaro E., Reggio D., De Angelis C., Rizzone M., Lopiano L. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J. Neurol. 2013;260(1):105–114. []. [PMID: 22772358].
    1. Zibetti M., Merola A., Artusi C.A., Rizzi L., Angrisano S., Reggio D., De Angelis C., Rizzone M., Lopiano L. Levodopa/ carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur. J. Neurol. 2014;21(2):312–318. [http:// ]. [PMID: 24313838].
    1. Müller T. Motor complications, levodopa metabolism and progression of Parkinson’s disease. Expert Opin. Drug Metab. Toxicol. 2011;7(7):847–855. [. 575779]. [PMID: 21480824].
    1. Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev. Neurother. 2013;13(6):707–718. []. [PMID: 23739007].
    1. Müller T., van Laar T., Cornblath D.R., Odin P., Klostermann F., Grandas F.J., Ebersbach G., Urban P.P., Valldeoriola F., Antonini A. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat. Disord. 2013;19(5):501–507. [ j.parkreldis.2013.02.006]. [PMID: 23453891].
    1. Uncini A., Eleopra R., Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J. Neurol. Neurosurg. Psychiatry. 2015;86(5):490–495. []. [PMID: 25168395].
    1. Caraco Y., Oren S., Yacoby-Zeevi O., Lewitt P., Giladi N. ND0612, a novel formulation of levodopa/carbidopa for continuous, subcutaneous administration, achieves steady-state levodopa plasma concentration in Parkinson’s disease patients.; Proceedings of the 17th International Congress of Parkinson’s Disease and Movement Disorders, LBA26; Sydney. 2015.
    1. Caraco Y., Oren S., LeWitt P. Constant therapeutic levodpa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/ carbidopa (CD). Mov. Disord. 2013;28:S162.
    1. Giladi N., Caraco Y., Gurevich T., Djaldetti R. 2015.
    1. Giladi N., Caraco Y., Gurevich T.R., Djaldetti Y., Cohen O. 2015.
    1. Luinstra M., Grasmeijer F., Hagedoorn P., Moes J.R., Frijlink H.W., de Boer A.H. A levodopa dry powder inhaler for the treatment of Parkinson’s disease patients in off periods. 2015.
    1. Lipp M.M., Batycky R., Moore J., Leinonen M., Freed M.I. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci. Transl. Med. 2016;8(360):360ra136. []. [PMID: 27733560].
    1. LeWitt P.A., Hauser R.A., Grosset D.G., Stocchi F., Saint-Hilaire M-H., Ellenbogen A., Leinonen M., Hampson N.B., DeFeo-Fraulini T., Freed M.I., Kieburtz K.D. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov. Disord. 2016;31(9):1356–1365. [ 10.1002/mds.26611]. [PMID: 27090868].

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj